Clinical Trials Logo
  1. Home
  2. Non-Small-Cell Lung Carcinoma
  3. NCT00727350

Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.

Non Small Cell Lung Carcinoma Clinical Trial

Official title:
Phase II Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.

Clinical Trial Summary

The study population will exist of patients with a histological diagnosis of NSCLC, stage T1, T2 or T3NO who are not fit for or who refuse surgery. A prospective data analysis will be performed on tumor response, potential acute and late toxicity and survival. A radiotherapy dose of 4x15Gy or 3x 20Gy will be given over 2 weeks with dynamic 3D-conformal arc therapy (Novalis TM)

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00727350
Study type Interventional
Source AZ-VUB
Contact Samuel Bral, MD
Phone 00324763435
Email samuel.bral@uzbrussel.be
Status Recruiting
Phase Phase 2
Start date March 2007
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01229150 - Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... Phase 2
Terminated NCT00592007 - Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer Phase 2
Completed NCT00199758 - Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer Phase 2
Completed NCT01999738 - Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Phase 1
Completed NCT01941316 - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Phase 1/Phase 2
Completed NCT00111839 - Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Phase 2
Completed NCT00181532 - Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC Phase 2
Completed NCT00864266 - Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer N/A
Completed NCT00890903 - Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) N/A
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Completed NCT01209520 - Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy N/A
Active, not recruiting NCT00759382 - Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Completed NCT00087711 - A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Phase 3
Completed NCT00252798 - ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer Phase 1
Completed NCT02938624 - Anti PD-1 Neo-adjuvant Treatment for NSCLC Phase 1
Terminated NCT00661011 - Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy Phase 2
Completed NCT00608868 - SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Phase 4
Terminated NCT00234468 - Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC Phase 3
Completed NCT00193921 - Chemoradiotherapy in Patients With Localised Lung Cancer Phase 2
Completed NCT00252746 - ZD6474 Phase IIa Dose Finding Multicentre Study Phase 2